| 赵颖洁,雷秀娟,袁业伟,张洁妤,高 霞,莫云路.女性乳腺浸润性导管癌组织USP18、USP20、USP25与临床病理特征和预后的关系研究[J].现代生物医学进展英文版,2024,(15):2995-30000. |
| 女性乳腺浸润性导管癌组织USP18、USP20、USP25与临床病理特征和预后的关系研究 |
| Study on the Relationship between USP18, USP20, USP25 and Clinicopathological Features and Prognosis in Female Breast Invasive Ductal Carcinoma |
| Received:January 21, 2024 Revised:February 18, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.15.037 |
| 中文关键词: 乳腺浸润性导管癌 USP18 USP20 USP25 临床病理特征 预后 |
| 英文关键词: Breast invasive ductal carcinoma USP18 USP20 USP25 Clinicopathologic features Prognosis |
| 基金项目:四川省妇幼保健协会妇幼医学科技创新课题（22FXZD03） |
|
| Hits: 72 |
| Download times: 46 |
| 中文摘要: |
| 摘要 目的：探讨女性乳腺浸润性导管癌组织中泛素特异性蛋白酶18（USP18）、泛素特异性蛋白酶20（USP20）、泛素特异性蛋白酶25（USP25）的表达与临床病理特征和预后的关系。方法：选取2017年3月-2020年3月四川省妇幼保健院和雅安市人民医院收治的女性乳腺浸润性导管癌患者98例作为研究对象，采用免疫组织化学方法检测乳腺浸润性导管癌组织和癌旁组织USP18、USP20、USP25的表达情况，分析癌组织中USP18、USP20和USP25的表达与临床病理特征间的关系。 多因素Logistic 回归分析女性乳腺浸润性导管癌预后的独立危险因素。Kaplan-Meier生存曲线分析USP18、USP20、USP25阴性和阳性表达患者预后的差异。结果：乳腺浸润性导管癌组织中USP20、USP18、USP25阳性表达率较癌旁组织更高（P<0.05）；乳腺浸润性导管癌组织中USP20的阳性表达与分化程度、TNM分期有关（P<0.05）；USP18的阳性表达与TNM分期、淋巴结转移、分子亚型、分化程度有关（P<0.05）；USP25的阳性表达与淋巴结转移及分化程度有关（P<0.05）。多因素 Logistic回归分析显示淋巴结转移、TNM III期、USP18阳性表达、USP20阳性表达、USP25阳性表达均是影响患者预后的独立危险因素（P<0.05）。Kaplan-Meier生存曲线发现USP18、USP20、USP25阳性表达患者的3年未复发生存率分别为59.65%、59.32%、58.62%，分别低于USP18、USP20、USP25阴性表达患者的82.05%、83.78%、84.21%。结论：USP18、USP20、USP25在女性乳腺浸润性导管癌中的表达情况与淋巴结转移、TNM分期、分化程度以及分子亚型密切相关。USP18、USP20、USP25阳性表达是影响患者预后的独立危险因素，且与患者3年未复发生存率有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between the expression of ubiquitin-specific protease 18 (USP18), ubiquitin-specific protease 20 (USP20), ubiquitin-specific protease 25 (USP25) and clinicopathological features and prognosis in female breast invasive ductal carcinoma. Methods: 98 female patients with breast invasive ductal carcinoma admitted to Sichuan Provincial Maternity and Child Health Care Hospital and Ya'an People's Hospital from March 2017 to March 2020 were selected as the research objects, the expression of USP18, USP20 and USP25 in breast invasive ductal carcinoma tissues and adjacent tissues was detected by immunohistochemical methods, and the relationship between the expression of USP18, USP20 and USP25 in cancer tissues and clinicopathological features was analyzed. The independent risk factors for the prognosis of female breast invasive ductal carcinoma were analyzed by multivariat Logistic regression. The difference in prognosis between patients with negative and positive expression of USP18, USP20 and USP25 were analyzed by Kaplan-Meier survival curve. Results: The positive expression rates of USP20, USP18 and USP25 in breast invasive ductal carcinoma tissues were higher than those in adjacent tissues (P<0.05). The positive expression of USP20 in breast invasive ductal carcinoma was related to the degree of differentiation and TNM stage (P<0.05). The positive expression of USP18 was correlated with TNM stage, lymph node metastasis, molecular subtype and differentiation degree (P<0.05). The positive expression of USP25 was related to lymph node metastasis and differentiation (P<0.05). Multivariate Logistic regression analysis showed that lymph node metastasis, TNM stage III, positive expression of USP18, positive expression of USP20 and positive expression of USP25 were independent risk factors affecting the prognosis of patients (P<0.05). Kaplan-Meier survival curve showed that the 3-year recurrence-free survival rates of patients with positive expression of USP18, USP20 and USP25 were 59.65%, 59.32% and 58.62% respectively, which were lower than 82.05%, 83.78% and 84.21% of patients with negative expression of USP18, USP20 and USP25 respectively. Conclusion: The expression of USP18, USP20, and USP25 in invasive ductal carcinoma of the female breast is closely related to lymph node metastasis, TNM staging, differentiation degree, and molecular subtypes. Positive expression of USP18, USP20, and USP25 is an independent risk factor affecting patient prognosis and is associated with a 3-year recurrence free survival rate. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
